Nothing Special   »   [go: up one dir, main page]

AR051931A1 - Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes - Google Patents

Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes

Info

Publication number
AR051931A1
AR051931A1 ARP050104239A ARP050104239A AR051931A1 AR 051931 A1 AR051931 A1 AR 051931A1 AR P050104239 A ARP050104239 A AR P050104239A AR P050104239 A ARP050104239 A AR P050104239A AR 051931 A1 AR051931 A1 AR 051931A1
Authority
AR
Argentina
Prior art keywords
estrogen
phase
daily dose
progestin
regimes
Prior art date
Application number
ARP050104239A
Other languages
English (en)
Original Assignee
Duramed Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duramed Pharmaceuticals Inc filed Critical Duramed Pharmaceuticals Inc
Publication of AR051931A1 publication Critical patent/AR051931A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Regímenes de ciclos extendidos con dosis ascendentes en los que se administra un estrogeno y una progestina a una hembra durante un período de más de 30 a 31 días consecutivos, opcionalmente seguido por un período son hormonas o por un período de administracion de estrogeno. Los regímenes descriptos pueden administrarse a una hembra para proporcionar beneficios anticonceptivos y no anticonceptivos. Kits farmacéuticos. Reivindicacion 1: Un método anticonceptivo, el método comprende: administrar a una hembra que lo necesita un estrogeno y una progestina durante un período de más de 30 días consecutivos; en el cual el estrogeno y la progestina se administran por lo menos en tres fases; en el cual una dosis diaria de estrogeno en una segunda fase es igual o mayor que una dosis diaria de estrogeno en una primera fase; en el cual una dosis diaria de estrogeno en una tercera fase es igual o mayor que la dosis diaria de estrogeno en la segunda fase; en el cual una dosis diaria total de estrogeno y progestina en la segunda fase es mayor que una dosis diaria total de estrogeno y progestina en la primera fase; y en el cual una dosis diaria total de estrogeno y progestina en la tercera fase es mayor que la dosis diaria total de estrogeno y progestina en la segunda fase.
ARP050104239A 2004-10-07 2005-10-07 Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes AR051931A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61642404P 2004-10-07 2004-10-07
US68456805P 2005-05-26 2005-05-26

Publications (1)

Publication Number Publication Date
AR051931A1 true AR051931A1 (es) 2007-02-21

Family

ID=36001184

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104239A AR051931A1 (es) 2004-10-07 2005-10-07 Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes

Country Status (11)

Country Link
US (1) US20060135496A1 (es)
EP (3) EP2392333A1 (es)
JP (1) JP2008515909A (es)
AR (1) AR051931A1 (es)
AU (1) AU2005294269B2 (es)
BR (1) BRPI0516247A (es)
CA (1) CA2582530A1 (es)
IL (1) IL182287A0 (es)
MX (1) MX2007004120A (es)
TW (1) TW200626161A (es)
WO (1) WO2006042021A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032756A1 (en) * 1995-10-28 2005-02-10 Michael Dittgen Multistage preparation for contraception based on natural estrogens
EP1453521B1 (en) * 2001-12-05 2013-09-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
AU2003230321B8 (en) * 2002-05-09 2009-07-30 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
DE102004019743B4 (de) * 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8153616B2 (en) * 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
WO2007143607A2 (en) 2006-06-02 2007-12-13 Pear Tree Women's Health Care Method of treating atrophic vaginitis
EP1930010A1 (de) * 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
UA101474C2 (ru) * 2007-02-06 2013-04-10 Колумбиа Лабораторис (Бермуда) Лимитед Применение прогестерона для производства лекарственного средства
WO2010042612A1 (en) 2008-10-08 2010-04-15 Agile Therapeutics, Inc. Transdermal delivery
EP2343964A4 (en) 2008-10-08 2012-11-07 Agile Therapeutics Inc TRANSDERMAL ADMINISTRATION
US9198876B2 (en) 2008-10-08 2015-12-01 Agile Therapeutics, Inc. Contraceptive transdermal delivery of hormones
CA2756222A1 (en) 2009-03-27 2010-09-30 Agile Therapeutics, Inc. Transdermal delivery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4616006A (en) * 1983-09-26 1986-10-07 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4628051A (en) * 1983-09-26 1986-12-09 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4530839A (en) * 1983-09-26 1985-07-23 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4544554A (en) * 1983-09-26 1985-10-01 Ortho Pharmaceutical Corporation Triphasic oral contraceptive
US4962098A (en) * 1987-06-15 1990-10-09 Warner-Lambert Company Graduated estrogen contraceptive
US5010070A (en) * 1987-06-15 1991-04-23 Warner-Lambert Company Graduated estrogen contraceptive
DK174724B1 (da) 1986-07-15 2003-10-06 Wyeth Corp Anvendelse af et præparat omfattende et østrogen og et progestogen til fremstilling af en dosisform til tilvejebringelse af hormonerstatningsterapi og kontraception til kvinder i præmenopausen samt pakning til tilvejebringelse af præparatet
IE71203B1 (en) * 1990-12-13 1997-02-12 Akzo Nv Low estrogen oral contraceptives
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive
US5858405A (en) * 1996-07-26 1999-01-12 American Home Products Corporation Oral contraceptive
AU3888597A (en) * 1996-07-26 1998-02-20 American Home Products Corporation Oral contraceptive
US6028064A (en) * 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5898032A (en) * 1997-06-23 1999-04-27 Medical College Of Hampton Roads Ultra low dose oral contraceptives with less menstrual bleeding and sustained efficacy
US6251956B1 (en) * 1998-08-20 2001-06-26 Ortho Pharmaceutical Corporation Combination progestin oral contraceptive regimen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
US7297688B2 (en) * 2000-06-08 2007-11-20 Wyeth Starter kit for low dose oral contraceptives
EP1453521B1 (en) * 2001-12-05 2013-09-04 Teva Women's Health, Inc. Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US20030219471A1 (en) * 2002-03-11 2003-11-27 Caubel Patrick Michel Extended cycle estrogen and sulfatase inhibiting progestogen contraceptive regimens
BR0309032A (pt) * 2002-04-03 2005-02-01 Barr Lab Inc Método para tratar sintomas vasomotores, a menopausa, deficiências hormonais em um paciente, e para tratar um paciente que sofre de sintomas vasomotores
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
BRPI0414945A (pt) * 2003-10-01 2006-11-07 Janssen Pharmaceutica Nv regimes contraceptivos trifásicos estendidos
US20070111975A1 (en) * 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens

Also Published As

Publication number Publication date
MX2007004120A (es) 2007-06-15
JP2008515909A (ja) 2008-05-15
EP2392333A1 (en) 2011-12-07
EP2392332A1 (en) 2011-12-07
EP1814556A2 (en) 2007-08-08
WO2006042021A3 (en) 2006-06-08
IL182287A0 (en) 2008-04-13
TW200626161A (en) 2006-08-01
WO2006042021B1 (en) 2006-08-03
BRPI0516247A (pt) 2008-08-26
CA2582530A1 (en) 2006-04-20
WO2006042021A2 (en) 2006-04-20
AU2005294269B2 (en) 2011-07-28
US20060135496A1 (en) 2006-06-22
AU2005294269A1 (en) 2006-04-20

Similar Documents

Publication Publication Date Title
AR051931A1 (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclos extendidos con dosis ascendentes
BRPI0412493A (pt) métodos de tratamento hormonal utilizando regimes contraceptivos com administração contìnua de estrogênio
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
CU20110100A7 (es) Tratamiento de pirfenidona para pacientes con función hepática atípica
UY27789A1 (es) Metodos y modalidades de dosificación para la liberación controlada de oxicodona.
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
CO4970819A1 (es) Tratamiento de disfuncion sexual femenina en una hembra humana
RS51688B (en) METHOTREXATE CONCENTRATED SOLUTIONS
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
ATE347358T1 (de) Schwimmende orale formulierungen mit kontrollierter freisetzung von betain
AR065816A1 (es) Regimen anticonceptivo oral
AR036312A1 (es) Composicion farmaceutica
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NO20061937L (no) Utvidet trefaseprevansjonskur
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
JP2014510780A5 (es)
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
AR056694A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
AR039546A1 (es) Terapia de reemplazo hormonal
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
AR039547A1 (es) Terapia de reemplazo hormonal
HRP20110718T1 (hr) UPOTREBA 7-t-BUTOKSIIMINOMETILKAMPTOTECINA U LIJEČENJU NOVOTVORINA MATERNICE
AR048068A1 (es) Piperazinas derivadas de urea para el tratamiento de endometriosis

Legal Events

Date Code Title Description
FB Suspension of granting procedure